Skip to main content

Table 1 Clinicopathological characteristics of the four TNBC subtypes based on the FUSCC classification criteria

From: Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

   FUSCC subtypes  
Characteristics Number IM LAR MES BLIS P
(total = 165) n = 28 n = 29 n = 55 n = 53
Age, y       0.024
 ≤50 68 14 (50.0) 6 (20.7) 20 (36.4) 28 (52.8)  
 >50 97 14 (50.0) 23 (79.3) 35 (63.6) 25 (47.2)  
Menopause       0.160
 Yes 101 16 (57.1) 23 (79.3) 33 (60.0) 29 (54.7)  
 No 64 12 (42.9) 6 (20.7) 22 (40.0) 24 (45.3)  
Tunor size, cm       0.409
 ≤2 cm 58 14 (50.0) 12 (41.4) 15 (27.3) 17 (32.1)  
 >2 cm 104 13 (46.4) 17 (58.6) 39 (70.9) 35 (66.0)  
 Unknown 3 1 (3.6) 0 (0.0) 1 (1.8) 1 (1.9)  
Tumor grade       0.311
  ≤ II 32 4 (14.3) 9 (31.0) 13 (23.6) 6 (11.3)  
  > II 104 17 (60.7) 17 (58.6) 33 (60.0) 37 (69.8)  
 Unknown 29 7 (25.0) 3 (10.3) 9 (16.4) 10 (18.9)  
Ki67, %       0.286
 <14 8 0 (0.0) 0 (0.0) 3 (5.5) 5 (9.4)  
 ≥14 156 28 (100.0) 29 (100.0) 51 (92.7) 48 (90.6)  
 Unknown 1 0 (0.0) 0 (0.0) 1 (1.8) 0 (0.0)  
Positive lymph nodes       0.019
 0 86 8 (28.6) 13 (44.8) 28 (50.9) 37 (69.8)  
 1-3 29 6 (21.4) 5 (17.2) 10 (18.2) 8 (15.1)  
  > 3 50 14 (50.0) 11 (37.9) 17 (30.9) 8 (15.1)  
Chemotherapy       0.642
 Taxane-based 124 21 (75.0) 22 (75.9) 42 (76.4) 39 (73.6)  
 Non-taxane-based 27 5 (17.9) 3 (10.3) 11 (20.0) 8 (15.1)  
 Unknown 14 2 (7.1) 4 (13.8) 2 (3.6) 6 (11.3)  
Radiotherapy       0.038
 Yes 50 16 (57.1) 9 (31.0) 14 (25.5) 11 (20.8)  
 No 103 11 (39.3) 20 (69.0) 37 (67.3) 35 (66.0)  
 Unknown 12 1 (3.6) 0 (0.0) 4 (7.3) 6 (11.3)  
Follow up, month       
 Median 13.9 14.7 12.4 14.3 12.6  
 IQR 8.6–21.1 10.0–22.4 8.6–19.0 10.6–21.5 8.0–18.4  
RFS events 22 5 4 4 9  
  1. BLIS basal-like and immune suppressed, FUSCC Fudan University Shanghai Cancer Center, IM immunomodulatory, IQR interquartile range, LAR luminal androgen receptor, MES mesenchymal-like, RFS recurrence-free survival